skip to content
Home

The Abell Group

Dr Anthony Coyne

Senior Research Associate

 

 

Publications

Development of potent inhibitors by fragment-linking strategies.
E Bedwell, WJ McCarthy, AG Coyne, C Abell
– Chemical Biology & Drug Design
(2022)
(DOI: 10.1111/cbdd.14120)
Structural Characterization of Mycobacterium abscessus Phosphopantetheine Adenylyl Transferase Ligand Interactions: Implications for Fragment-Based Drug Design
SE Thomas, WJ McCarthy, J El Bakali, KP Brown, SY Kim, M Blaszczyk, V Mendes, C Abell, RA Floto, AG Coyne, TL Blundell
– Frontiers in Molecular Biosciences
(2022)
9,
880432
(DOI: 10.3389/fmolb.2022.880432)
Potential therapeutic targets from Mycobacterium abscessus (Mab): recently reported efforts towards the discovery of novel antibacterial agents to treat Mab infections
W Addison, M Frederickson, AG Coyne, C Abell
– RSC Medicinal Chemistry
(2022)
13,
392
(DOI: 10.1039/d1md00359c)
Discovery of Novel Inhibitors of Uridine Diphosphate- N-Acetylenolpyruvylglucosamine Reductase (MurB) from Pseudomonas aeruginosa, an Opportunistic Infectious Agent Causing Death in Cystic Fibrosis Patients
M Acebrón-García-de-Eulate, J Mayol-Llinàs, MTO Holland, SY Kim, KP Brown, C Marchetti, J Hess, O Di Pietro, V Mendes, C Abell, RA Floto, AG Coyne, TL Blundell
– Journal of medicinal chemistry
(2022)
65,
2149
(DOI: 10.1021/acs.jmedchem.1c01684)
Development of Inhibitors of SAICAR Synthetase (PurC) from Mycobacterium abscessus Using a Fragment-Based Approach.
S Charoensutthivarakul, SE Thomas, A Curran, KP Brown, JM Belardinelli, AJ Whitehouse, M Acebrón-García-de-Eulate, J Sangan, SG Gramani, M Jackson, V Mendes, RA Floto, TL Blundell, AG Coyne, C Abell
– ACS Infect Dis
(2022)
8,
296
(DOI: 10.1021/acsinfecdis.1c00432)
A new strategy for hit generation: Novel in cellulo active inhibitors of CYP121A1 from Mycobacterium tuberculosis via a combined X-ray crystallographic and phenotypic screening approach (XP screen).
M Frederickson, IR Selvam, D Evangelopoulos, KJ McLean, MM Katariya, RB Tunnicliffe, B Campbell, ME Kavanagh, S Charoensutthivarakul, RT Blankley, CW Levy, LPS de Carvalho, D Leys, AW Munro, AG Coyne, C Abell
– European journal of medicinal chemistry
(2022)
230,
114105
(DOI: 10.1016/j.ejmech.2022.114105)
Targeting Mycobacterium tuberculosis CoaBC through Chemical Inhibition of 4'-Phosphopantothenoyl-l-cysteine Synthetase (CoaB) Activity.
JC Evans, D Murugesan, JM Post, V Mendes, Z Wang, N Nahiyaan, SL Lynch, S Thompson, SR Green, PC Ray, J Hess, C Spry, AG Coyne, C Abell, HIM Boshoff, PG Wyatt, KY Rhee, TL Blundell, CE Barry, V Mizrahi
– ACS Infectious Diseases
(2021)
7,
1666
(DOI: 10.1021/acsinfecdis.0c00904)
A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death
DE Scott, NJ Francis-Newton, ME Marsh, AG Coyne, G Fischer, T Moschetti, AR Bayly, TD Sharpe, KT Haas, L Barber, CR Valenzano, R Srinivasan, DJ Huggins, M Lee, A Emery, B Hardwick, M Ehebauer, C Dagostin, A Esposito, L Pellegrini, T Perrior, G McKenzie, TL Blundell, M Hyvönen, J Skidmore, AR Venkitaraman, C Abell
– Cell Chemical Biology
(2021)
28,
1
(DOI: 10.1016/j.chembiol.2021.02.006)
Chris Abell 1957–2020
FJ Leeper, AG Coyne
– The Biochemist
(2021)
43,
45
(DOI: 10.1042/bio_2021_106)
Inhibiting Mycobacterium tuberculosis CoaBC by targeting an allosteric site.
V Mendes, SR Green, JC Evans, J Hess, M Blaszczyk, C Spry, O Bryant, J Cory-Wright, DS-H Chan, PHM Torres, Z Wang, N Nahiyaan, S O'Neill, S Damerow, J Post, T Bayliss, SL Lynch, AG Coyne, PC Ray, C Abell, KY Rhee, HIM Boshoff, CE Barry, V Mizrahi, PG Wyatt, TL Blundell
– Nature Communications
(2021)
12,
143
(DOI: 10.1038/s41467-020-20224-x)
  • 1 of 8
  • >

Telephone number

01223 336055

Email address

Study at Cambridge

About the University

Research at Cambridge